acquired
Stage
2
Investors
About
Prosensa was a biotechnology company spun out from Leiden University focused on developing RNA-modulating therapies for Duchenne muscular dystrophy, later acquired by BioMarin Pharmaceuticals.
Explore Prosensa's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.